Cargando…
Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma
INTRODUCTION: Renal insufficiency (RI) in Multiple Myeloma (MM) portends a higher tumor burden and worse prognosis. Reversal of RI in newly diagnosed MM (NDMM) improves patient outcomes, but it is unknown if there is a disparity in renal recovery in NDMM between African Americans (AA) and non-Africa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145056/ https://www.ncbi.nlm.nih.gov/pubmed/30254762 http://dx.doi.org/10.1155/2018/4654717 |
_version_ | 1783356198084411392 |
---|---|
author | Derman, Benjamin A. Reiser, Jochen Basu, Sanjib Paner, Agne |
author_facet | Derman, Benjamin A. Reiser, Jochen Basu, Sanjib Paner, Agne |
author_sort | Derman, Benjamin A. |
collection | PubMed |
description | INTRODUCTION: Renal insufficiency (RI) in Multiple Myeloma (MM) portends a higher tumor burden and worse prognosis. Reversal of RI in newly diagnosed MM (NDMM) improves patient outcomes, but it is unknown if there is a disparity in renal recovery in NDMM between African Americans (AA) and non-African Americans. METHODS: A retrospective chart review was conducted of 690 patients with NDMM at Rush University Medical Center from 2005 to 2016. 118 patients (59 AA and 59 non-AA) with NDMM and an estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m(2) at the time of diagnosis were identified and analyzed. The time to best renal response and best eGFR achieved during initial myeloma therapy were tabulated. RESULTS: Median eGFR at the time of diagnosis was similar between the AA and non-AA groups (47.89 versus 51.95, p=0.56). Median absolute change in eGFR after initial therapy was significantly higher in the AA (+33.64) versus the non-AA group (+21.07, p=0.00183). This difference remained whether the baseline eGFR at diagnosis was <90 or <60 mL/min/1.73 m(2). DISCUSSION: AA patients with NDMM treated in the era of novel agents have greater improvement in renal function in comparison to non-AA patients, regardless of myeloma response. The biological underpinnings for this disparity require further investigation. |
format | Online Article Text |
id | pubmed-6145056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-61450562018-09-25 Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma Derman, Benjamin A. Reiser, Jochen Basu, Sanjib Paner, Agne Int J Nephrol Research Article INTRODUCTION: Renal insufficiency (RI) in Multiple Myeloma (MM) portends a higher tumor burden and worse prognosis. Reversal of RI in newly diagnosed MM (NDMM) improves patient outcomes, but it is unknown if there is a disparity in renal recovery in NDMM between African Americans (AA) and non-African Americans. METHODS: A retrospective chart review was conducted of 690 patients with NDMM at Rush University Medical Center from 2005 to 2016. 118 patients (59 AA and 59 non-AA) with NDMM and an estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m(2) at the time of diagnosis were identified and analyzed. The time to best renal response and best eGFR achieved during initial myeloma therapy were tabulated. RESULTS: Median eGFR at the time of diagnosis was similar between the AA and non-AA groups (47.89 versus 51.95, p=0.56). Median absolute change in eGFR after initial therapy was significantly higher in the AA (+33.64) versus the non-AA group (+21.07, p=0.00183). This difference remained whether the baseline eGFR at diagnosis was <90 or <60 mL/min/1.73 m(2). DISCUSSION: AA patients with NDMM treated in the era of novel agents have greater improvement in renal function in comparison to non-AA patients, regardless of myeloma response. The biological underpinnings for this disparity require further investigation. Hindawi 2018-09-05 /pmc/articles/PMC6145056/ /pubmed/30254762 http://dx.doi.org/10.1155/2018/4654717 Text en Copyright © 2018 Benjamin A. Derman et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Derman, Benjamin A. Reiser, Jochen Basu, Sanjib Paner, Agne Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma |
title | Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma |
title_full | Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma |
title_fullStr | Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma |
title_full_unstemmed | Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma |
title_short | Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma |
title_sort | renal dysfunction and recovery following initial treatment of newly diagnosed multiple myeloma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145056/ https://www.ncbi.nlm.nih.gov/pubmed/30254762 http://dx.doi.org/10.1155/2018/4654717 |
work_keys_str_mv | AT dermanbenjamina renaldysfunctionandrecoveryfollowinginitialtreatmentofnewlydiagnosedmultiplemyeloma AT reiserjochen renaldysfunctionandrecoveryfollowinginitialtreatmentofnewlydiagnosedmultiplemyeloma AT basusanjib renaldysfunctionandrecoveryfollowinginitialtreatmentofnewlydiagnosedmultiplemyeloma AT paneragne renaldysfunctionandrecoveryfollowinginitialtreatmentofnewlydiagnosedmultiplemyeloma |